ACGT Awards Luncheon Honors Crystal Mackall, MD, With Edward Netter Leadership Award

Article

Alliance for Cancer Gene Therapy (ACGT) awarded The Edward Netter Leadership Award to Crystal Mackall, MD, of Stanford University.

Alliance for Cancer Gene Therapy (ACGT) awarded The Edward Netter Leadership Award to Crystal Mackall, MD, of Stanford University, at the ACGT Awards Luncheon on March 30 at Riverpark restaurant at the Alexandria Center for Life Science in New York City.

Crystal Mackall, MD Edward Netter Leadership Award | Image Credit: ACGT

Crystal Mackall, MD, right, received The Edward Netter Leadership Award during the ACGT Awards Luncheon earlier this year. Carl June, MD, left, the 2019 recipient of the award, presented it to Dr. Mackall.

The ACGT Awards Luncheon celebrated the non-profit organization’s 20th anniversary and ushered in a new decade. The event was held during the intermission of the ACGT Summit 2023.

Attendees, including scientists and donors, helped ACGT recognize Dr. Mackall for her incredible achievements, such as the numerous groundbreaking clinical trials she has led to treat children with sarcomas and brain cancers. Named for ACGT co-founder, Edward Netter, the award recognizes a researcher who has made unparalleled and groundbreaking contributions to the field of cell and gene therapy for cancer.

“Without the donors, Alliance for Cancer Gene Therapy doesn’t exist,” Dr. Mackall said, later adding that “you get (a foundation like ACGT) by having a leadership with great instincts, leadership that is passionate, and leadership that has grit.”

Read more about Dr. Mackall’s recognition and the ACGT Awards Luncheon on the foundation’s website.

Related Videos
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
Fiona Freeman, PhD, on Investigating miRNA-29b in Osteosarcoma Models
Brian Van Tine, MD, PhD, on Progress and Challenges With Cell Therapy for Sarcoma
J. Andrew Livingston, MD, on Potential Advantages of TCR NK Therapy for Synovial Sarcoma and MRCL
Binod Dhakal, MD, on Benefit of Cilta-Cel in Earlier Lines of Multiple Myeloma Treatment
Thomas McCauley, PhD, on the Potential of Epigenetics for Therapy Development
J. Andrew Livingston, MD, and Brian Van Tine, MD, PhD, on Sarcoma Awareness Month 2023
Rebecca Cottman, PhD, on Enhancing Cell Therapy Cytotoxicity With a Regulated Gene Circuit
Related Content
© 2023 MJH Life Sciences

All rights reserved.